CG Oncology, Inc. · NASDAQ:CGON

CG Oncology — Investor Presentation (January 2024)

26 slides from CG Oncology's investor presentation, January 2024

  1. Slide 1: Attacking Bladder Cancer for a Better Tomorrow

    Attacking Bladder Cancer for a Better Tomorrow | 1

  2. Slide 2: Disclaimer and Forward-Looking Statements

    Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and

  3. Slide 3: Catalyst Rich Calendar Through Potential First Approval and Launch

    Catalyst Rich Calendar Through Potential First Approval and Launch Followed by Bladder Indication Expansion COMPOUND/INDICATION PHASE 1 PHASE 2 PHASE 3 ANTICIPATED MILESTONES BOND-003 topline High-Risk, BCG-Unresponsive NMIBC (BOND-003) data by the end of 2024 CORE-001 additional High-Risk, BCG-Unre

  4. Slide 4: The CG Oncology Team

    The CG Oncology Team q Arthur Kuan Ambaw Bellete CEO & Board Director President & COO fe S Proven Executive Management Team a Lied _ MOFFITT @) &. y oot S SANOFI Deep Industry Experience with Track Record of Success in Oncology Development A Swapnil Bhargava, Ph.D. Corleen Roche Chief Technical Offi

  5. Slide 5: Attacking Bladder Cancer for a Better Tomorrow

    Attacking Bladder Cancer for a Better Tomorrow | 5

  6. Slide 6: Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers

    Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers Cretostimogene grenadenorepvec Cretostimogene grenadenorepvec in Normal Cells in Tumor Cells o o | 6

  7. Slide 7: Cretostimogene Administration

    Dwell DDM min 15 Normal Sali h r ne W as Laye ash W AG M D ove G D m re To GAG Layer Tumor h mal Saline Was Cretostimogen 45-60 min e Dwe Nor utes ll Catheter Cretostimogene | 7

  8. Slide 8: Targeted Dual Mode of Action Designed to Produce Selective Oncolysis

    Targeted Dual Mode of Action Designed to Produce Selective Oncolysis To Trigger Potent Anti-Tumor Immune Response Virus enters cells Bladder endothelial Virus spreads tissue to other tumors Lamina Propria Virus replicates Cytokines and Smooth and kills antigens release muscle cancer cells tissue | 8

  9. Slide 9: Bladder Cancer is a Significant Unmet Medical Need

    Bladder Cancer is a Significant Unmet Medical Need Well Positioned for Innovation and Disruption | 9

  10. Slide 10: NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer

    NMIBC Represents a Multi-Billion insice othe Bladder wall Outside of the bladder wall bladder wall Dollar Market Opportunity in i Bladder Cancer Nonttusdeinmnive fl cis fl Bladder Cancer NMIBC Carcinoma in Situ (CIS) Non-Invasive Te Papillary Carcinoma Tumor Invades Connective Tissue ~75% of Newly D

  11. Slide 11: Patient Journey and Ongoing Treatment

    (1) Symptom Ongoing Treatment Require surveillance and/or Patient presents to primary care treatment every 3 to 6 months and/or urologist with symptoms for 2 to 5 years (hematuria, urinary frequency) Testing Work-up may include cystoscopy, urine cytology, LR: and imaging (CT scan, MRI) ¥ Low-Risk Pe

  12. Slide 12: FDA Guidance on BCG-Unresponsive NMIBC De-Risks Development & Regulatory Pathway

    FDA Guidance on BCG-Unresponsive NMIBC De-Risks Development & Regulatory Pathway to BLA Approval Single-arm trials with complete response rate as primary endpoint in the context of duration of response may be appropriate for a full approval. BCG-unresponsive disease defined as either: • Persistent o

  13. Slide 13: Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets

    Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets with Multi-Billion Dollar Potential | 13

  14. Slide 14: Phase 3 Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive NMIBC

    Phase 3 Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive NMIBC (NCT04452591) CR at Any Time (CIS) Single-Arm, Open-Label, IVe Administration EFS (Ta/T1) Population Study Design / Regimen Additional Endpoints • • • • • • • • • • • • • • • • | 14

  15. Slide 15: Patient Demographics & Baseline Characteristics

    Patient Demographics & Baseline Characteristics • • | 15

  16. Slide 16: First Results From BOND-003: 75.7% CR at Any Time

    First Results From BOND-003: 75.7% CR at Any Time | 16

  17. Slide 17: SUO 2023: First Results from BOND-003

    CORE-001 SUO 2023: First Results from BOND-003 Cretostimogene Monotherapy for BCG-Unresponsive NMIBC Key Highlights from SUO 2023: ▪ ▪ ▪ Patients 76% (50/66) 68% (45/66) 64% (42/66) 84% (42/50) 74% (32/43) | 17

  18. Slide 18: Cretostimogene Has Been Generally Well-Tolerated With No Grade 3 Or Higher Treatment-Related AEs

    Cretostimogene Has Been Generally Well-Tolerated With No Grade 3 Or Higher Treatment-Related AEs Top Adverse Events Considered Related to Cretostimogene Administration For All Patients (n=112) By Grade | 18

  19. Slide 19: Pioneering First-in-Class Oncolytic Immunotherapy with Differentiated Clinical Profile

    Pioneering First-in-Class Oncolytic Immunotherapy with Differentiated Clinical Profile Against Approved NMIBC Agents1 Trial BOND-003 NCT02773849 KEYNOTE-057 Intervention Mechanism RoA Stage Sample Size CR Any Time CR 6 Mo CR 12 Mo Safety Profile | 19

  20. Slide 20: Phase 2 Cretostimogene + Pembrolizumab for High-Risk, BCG-Unresponsive NMIBC

    Phase 2 Cretostimogene + Pembrolizumab for High-Risk, BCG-Unresponsive NMIBC, CIS-Containing (NCT04387461) CR at 12-months Single-Arm, Open-Label, IVe Creto + IV Pembrolizumab Population Study Design / Regimen Additional Endpoints • • • • • • • • • • • | 20

  21. Slide 21: AUA 2023: Updated Interim Data in CORE-001 Study

    CORE-001 AUA 2023: Updated Interim Data in CORE-001 Study Cretostimogene + Pembrolizumab Combo for BCG-Unresponsive NMIBC Ongoing Response Complete Response Recurrence / Non-Response Second Induction Discontinued Study 85% (29/34) 82% (27/33) 81% (25/31) 68% (17/25) | 21

  22. Slide 22: Tolerable Interim Safety Results in PD-1 Checkpoint Combo

    Tolerable Interim Safety Results with Acceptable Immune-Related AE Within Expectations in PD-1 Checkpoint Combo AUA 2023, Abstract #23-5631 - CORE-001: Phase 2 Single Arm Study of Creto Combined with Pembrolizumab in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-

  23. Slide 23: Phase 3 Adjuvant Cretostimogene Following TURBT Versus Observation for Intermediate Risk NMIBC

    Phase 3 Adjuvant Cretostimogene Following TURBT Versus Observation Following TURBT for Intermediate Risk NMIBC Randomized (1:1), Two Arms, Open-Label (n=426) RFS Rate Population Study Design / Regimen Additional Endpoints • • • • • • • • • • • • • • • | 23

  24. Slide 24: Phase 2 Cretostimogene Monotherapy Study for High-Risk, BCG-Exposed and BCG-Naïve NMIBC

    Phase 2 Cretostimogene Monotherapy Study for High-Risk, BCG-Exposed and BCG-Naïve NMIBC (Planned Study) Multi-Cohort, Open-Label (Up to n=60 per cohort) CR at Any Time Population Study Design / Regimen Additional Endpoints • • • • • • • • • • • • | 24

  25. Slide 25: CG Oncology Highlights

    CG Oncology Highlights 1 2 3 Attacking Bladder Cancer for a Better Tomorrow 4 5 | 25

  26. Slide 26: CG Oncology Inc. Contact Information

    CG Oncology Inc. [email protected] 400 Spectrum Center Dr Suite #2040 Irvine, CA 92618 [email protected] | 26

CG Oncology — Investor Presentation (January 2024) on 6ix